SLYND Drug Patent Profile
✉ Email this page to a colleague
When do Slynd patents expire, and when can generic versions of Slynd launch?
Slynd is a drug marketed by Exeltis Usa Inc and is included in one NDA. There are six patents protecting this drug and one Paragraph IV challenge.
This drug has fifty-one patent family members in twenty-seven countries.
The generic ingredient in SLYND is drospirenone. There are eleven drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the drospirenone profile page.
DrugPatentWatch® Generic Entry Outlook for Slynd
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be June 28, 2031. This may change due to patent challenges or generic licensing.
There is one Paragraph IV patent challenge for this drug. This may lead to patent invalidation or a license for generic production.
Indicators of Generic Entry
Summary for SLYND
International Patents: | 51 |
US Patents: | 6 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 69 |
Patent Applications: | 2,361 |
Formulation / Manufacturing: | see details |
Drug Prices: | Drug price information for SLYND |
What excipients (inactive ingredients) are in SLYND? | SLYND excipients list |
DailyMed Link: | SLYND at DailyMed |


DrugPatentWatch® Estimated Generic Entry Opportunity Date for SLYND
Generic Entry Date for SLYND*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
TABLET;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Anatomical Therapeutic Chemical (ATC) Classes for SLYND
Paragraph IV (Patent) Challenges for SLYND
Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
---|---|---|---|---|---|---|
SLYND | Tablets | drospirenone | 4 mg | 211367 | 1 | 2022-01-07 |
US Patents and Regulatory Information for SLYND
SLYND is protected by six US patents and one FDA Regulatory Exclusivity.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of SLYND is See Plans and Pricing.
This potential generic entry date is based on patent See Plans and Pricing.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
Patents protecting SLYND
Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: PREVENTION OF PREGNANCY IN FEMALES OF REPRODUCTIVE AGE
Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: PREVENTION OF PREGNANCY IN FEMALES OF REPRODUCTIVE AGE
Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: PREVENTION OF PREGNANCY IN FEMALES OF REPRODUCTIVE AGE
Synthetic progestogens and pharmaceutical compositions comprising the same
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Synthetic progestogens and pharmaceutical compositions comprising the same
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: PREVENTION OF PREGNANCY IN FEMALES OF REPRODUCTIVE AGE
FDA Regulatory Exclusivity protecting SLYND
NEW PRODUCT
Exclusivity Expiration: See Plans and Pricing
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Exeltis Usa Inc | SLYND | drospirenone | TABLET;ORAL | 211367-001 | May 23, 2019 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | See Plans and Pricing | ||||
Exeltis Usa Inc | SLYND | drospirenone | TABLET;ORAL | 211367-001 | May 23, 2019 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | See Plans and Pricing | ||||
Exeltis Usa Inc | SLYND | drospirenone | TABLET;ORAL | 211367-001 | May 23, 2019 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | Y | See Plans and Pricing | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for SLYND
When does loss-of-exclusivity occur for SLYND?
Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:
Argentina
Patent: 1670
Estimated Expiration: See Plans and Pricing
Australia
Patent: 11273605
Estimated Expiration: See Plans and Pricing
Brazil
Patent: 2012033391
Estimated Expiration: See Plans and Pricing
Patent: 2019008317
Estimated Expiration: See Plans and Pricing
Canada
Patent: 03721
Estimated Expiration: See Plans and Pricing
Patent: 03062
Estimated Expiration: See Plans and Pricing
Patent: 61421
Estimated Expiration: See Plans and Pricing
Chile
Patent: 12003685
Estimated Expiration: See Plans and Pricing
Colombia
Patent: 40328
Estimated Expiration: See Plans and Pricing
Croatia
Patent: 0200155
Estimated Expiration: See Plans and Pricing
Denmark
Patent: 88114
Estimated Expiration: See Plans and Pricing
Patent: 32448
Estimated Expiration: See Plans and Pricing
Ecuador
Patent: 12012359
Estimated Expiration: See Plans and Pricing
Patent: 15032906
Estimated Expiration: See Plans and Pricing
Patent: 15032911
Estimated Expiration: See Plans and Pricing
Eurasian Patent Organization
Patent: 8680
Estimated Expiration: See Plans and Pricing
Patent: 1291372
Estimated Expiration: See Plans and Pricing
European Patent Office
Patent: 88114
Estimated Expiration: See Plans and Pricing
Patent: 32448
Estimated Expiration: See Plans and Pricing
Guatemala
Patent: 1200336
Estimated Expiration: See Plans and Pricing
Patent: 1200336A
Estimated Expiration: See Plans and Pricing
Patent: 1200336B
Estimated Expiration: See Plans and Pricing
Hungary
Patent: 47689
Estimated Expiration: See Plans and Pricing
Patent: 000016
Estimated Expiration: See Plans and Pricing
Japan
Patent: 10159
Estimated Expiration: See Plans and Pricing
Patent: 13529665
Estimated Expiration: See Plans and Pricing
Lithuania
Patent: 2021523
Estimated Expiration: See Plans and Pricing
Patent: 88114
Estimated Expiration: See Plans and Pricing
Mexico
Patent: 9952
Estimated Expiration: See Plans and Pricing
Patent: 4971
Estimated Expiration: See Plans and Pricing
Patent: 12014629
Estimated Expiration: See Plans and Pricing
Patent: 19004393
Estimated Expiration: See Plans and Pricing
New Zealand
Patent: 5176
Estimated Expiration: See Plans and Pricing
Norway
Patent: 20015
Estimated Expiration: See Plans and Pricing
Peru
Patent: 130780
Estimated Expiration: See Plans and Pricing
Patent: 161410
Estimated Expiration: See Plans and Pricing
Poland
Patent: 88114
Estimated Expiration: See Plans and Pricing
Portugal
Patent: 88114
Estimated Expiration: See Plans and Pricing
Serbia
Patent: 826
Estimated Expiration: See Plans and Pricing
Slovenia
Patent: 88114
Estimated Expiration: See Plans and Pricing
South Africa
Patent: 1209743
Estimated Expiration: See Plans and Pricing
South Korea
Patent: 2164693
Estimated Expiration: See Plans and Pricing
Patent: 2210982
Estimated Expiration: See Plans and Pricing
Patent: 130048227
Estimated Expiration: See Plans and Pricing
Patent: 170085604
Estimated Expiration: See Plans and Pricing
Patent: 190073598
Estimated Expiration: See Plans and Pricing
Patent: 210013663
Estimated Expiration: See Plans and Pricing
Spain
Patent: 77886
Estimated Expiration: See Plans and Pricing
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
See the table below for additional patents covering SLYND around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Denmark | 3632448 | See Plans and Pricing | |
European Patent Office | 3632448 | COMPOSITION PHARMACEUTIQUE COMPRENANT DE LA DROSPIRÉNONE ET ENSEMBLE CONTRACEPTIF (PHARMACEUTICAL COMPOSITION COMPRISING DROSPIRENONE AND CONTRACEPTIVE KIT) | See Plans and Pricing |
Ecuador | SP12012359 | COMPOSICIÓN FARMACÉUTICA QUE COMPRENDE DROSPIRENONA Y KIT ANTICONCEPTIVO | See Plans and Pricing |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for SLYND
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
1380301 | 2009C/007 | Belgium | See Plans and Pricing | PRODUCT NAME: DROSPIRENONE-ETHINYLESTRADIOL; AUTHORISATION NUMBER AND DATE: BE321386 20080811 |
2588114 | LUC00227 | Luxembourg | See Plans and Pricing | PRODUCT NAME: DROSPIRENONE; AUTHORISATION NUMBER AND DATE: 31332 20191022 |
2588114 | CA 2020 00023 | Denmark | See Plans and Pricing | PRODUCT NAME: DROSPIRENON; NAT. REG. NO/DATE: 61678 20191016; FIRST REG. NO/DATE: DK 61678 20191016 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |